SECONDARY AND TERTIARY HYPERPARATHYROIDSIS IN CHRONIC KIDNEY DISEASE
Keywords:
Clinical case; secondary hyperparathyroidism; tertiary hyperparathyroidism; cinacalcet; parathyroidectomy; hemodialysis; kidney transplant.Abstract
Treatment goals for secondary hyperparathyroidism in patients with chronic kidney disease are aimed at preventing disease progression and suppressing parathyroid activity through modulation of vitamin D receptors and calcium-sensing receptors. However, treatment options are limited in severe hyperparathyroidism; monoclonal changes and nodular transformation of glands with loss of receptors for vitamin D and calcium form resistance to this therapy with the development of drug-uncontrolled hyperparathyroidism.
Downloads
References
Abe M, Okada K, Soma M. Mineral Metabolic Abnormalities and Mortality in Dialysis Patients. Nutrients. 2013;5(3):1002-1023. doi: 10.3390/nu5031002.
Goodman WG, Quarles LD. Development and progression of secondary hyperparathyroidism in chronic kidney disease:
lessons from molecular genetics. Kidney Int. 2018;74(3):276-288. doi: 10.1038/sj.ki.5002287.
Chertow GM, Dillon M, Burke SK, et al. A randomized trial of sevelam-er hydrochloride (RenaGel) with and without supplemental calcium. Strategies for the control of hyperphosphatemia and hyperparathyroidism in hemodialysis patients. Clin Nephrol. 2019;51(1):18-26.
Chertow GM, Lu ZJ, Xu X, et al. Self-reported symptoms in patients on hemodialysis with moderate to severe secondary hyperparathyroidism receiving combined therapy with cinacalcet and low-dose vitamin D sterols. Hemodialysis International. 2012;16(2):188-197. doi: 10.1111/j.1542-4758.2011.00642.x.
Downloads
Published
How to Cite
Issue
Section
License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.


